Tech Company Financing Transactions

Confo Therapeutics Funding Round

On 7/26/2024, Confo Therapeutics raised $65 million in Series B funding from Ackermans & Van Haaren, BioGeneration Ventures and Capricorn Healthcare.

Transaction Overview

Company Name
Announced On
7/26/2024
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series B
Proceeds Purpose
The company intends to use the funds to advance two, wholly owned programs through Phase 1 and two additional programs to IND approval, including molecules targeting GPR75 for obesity.

Company Information

Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Technologiepark-Zwijnaarde 30
Ghent/Zwijnaarde, 9052
Belgium
Phone
Undisclosed
Email Address
Overview
Confo Therapeutics' unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments.
Profile
Confo Therapeutics LinkedIn Company Profile
Social Media
Confo Therapeutics Company Twitter Account
Company News
Confo Therapeutics News
Facebook
Confo Therapeutics on Facebook
YouTube
Confo Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Cedric Ververken
  Cedric Ververken LinkedIn Profile  Cedric Ververken Twitter Account  Cedric Ververken News  Cedric Ververken on Facebook
Chief Financial Officer
Marc Moens
  Marc Moens LinkedIn Profile  Marc Moens Twitter Account  Marc Moens News  Marc Moens on Facebook
Chief Scientific Officer
Christel Menet
  Christel Menet LinkedIn Profile  Christel Menet Twitter Account  Christel Menet News  Christel Menet on Facebook
Chief Technical Officer
Toon Laeremans
  Toon Laeremans LinkedIn Profile  Toon Laeremans Twitter Account  Toon Laeremans News  Toon Laeremans on Facebook
VP - Bus. Development
Stephen Dowd
  Stephen Dowd LinkedIn Profile  Stephen Dowd Twitter Account  Stephen Dowd News  Stephen Dowd on Facebook
VP - Bus. Development
Paolo Vicini
  Paolo Vicini LinkedIn Profile  Paolo Vicini Twitter Account  Paolo Vicini News  Paolo Vicini on Facebook
VP - General Counsel
Frank Landolt
  Frank Landolt LinkedIn Profile  Frank Landolt Twitter Account  Frank Landolt News  Frank Landolt on Facebook


 

 

Browse more venture capital transactions:

Prev: 7/26/2024: Terrantic venture capital transaction
Next: 7/26/2024: Greenely venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary